MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ
8.15
-0.19
-2.28%
After Hours: 8.50 +0.35 +4.29% 19:32 05/15 EDT
OPEN
8.53
PREV CLOSE
8.34
HIGH
8.55
LOW
8.10
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
14.93
52 WEEK LOW
4.535
MARKET CAP
843.67M
P/E (TTM)
-5.6969
1D
5D
1M
3M
1Y
5Y
1D
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
TipRanks · 1d ago
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
TipRanks · 1d ago
Weekly Report: what happened at ORIC last week (0504-0508)?
Weekly Report · 5d ago
Oric Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 05/05 16:04
Oric Pharmaceuticals Price Target Cut to $16.00/Share From $17.00 by Citigroup
Dow Jones · 05/05 16:04
Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16
Benzinga · 05/05 15:54
Oric Pharmaceuticals (ORIC) Initiated with a Buy at Wedbush
TipRanks · 05/05 13:46
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Fortrea Holdings Inc. (FTRE) and Edwards Lifesciences (EW)
TipRanks · 05/05 12:30
More
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Webull offers ORIC Pharmaceuticals Inc stock information, including NASDAQ: ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.